A carregar...
Predictive Value of In Vitro Mutation Data to Guide Second-Generation Tyrosine Kinase Inhibitor Selection: Ready for Prime Time?
Significant advances in treatment and monitoring for patients with chronic myeloid leukemia have occurred over the last decade. With the introduction of the tyrosine kinase inhibitor imatinib, long-term outcomes have improved and new challenges, such as resistance, including mutations, have emerged....
Na minha lista:
| Autor principal: | |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
AlphaMed Press
2011
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3228184/ https://ncbi.nlm.nih.gov/pubmed/21450785 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2010-0297 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|